Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRPR | P30550 | 13/20 | 0.67 |
| ▸ | NMBR | P28336 | 2/20 | 0.53 |
| ▸ | GLP1R | P43220 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29484954 | 1.00 | GRPR (0.67) | GRPRNMBRGLP1R | |
| SCHEMBL30816315 | 0.97 | GRPR (0.63) | GRPRNMBRGLP1R | |
| SCHEMBL30398505 | 0.97 | GRPR (0.64) | GRPRNMBR | |
| SCHEMBL27378954 | 0.96 | GRPR (0.69) | GRPRNMBR | |
| SCHEMBL27379518 | 0.96 | GRPR (0.69) | GRPRNMBR | |
| SCHEMBL30118082 | 0.95 | GRPR (0.65) | GRPRGLP1R | |
| SCHEMBL25081963 | 0.95 | GRPR (0.69) | GRPRNMBR | |
| SCHEMBL25081959 | 0.95 | GRPR (0.69) | GRPRNMBR | |
| SCHEMBL24253292 | 0.95 | GRPR (0.69) | GRPRNMBR | |
| SCHEMBL24253291 | 0.95 | GRPR (0.69) | GRPRNMBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025215527-A2 | PHARMACEUTICAL COMBINATIONS AND USES THEREOF | NOVARTIS AG (CH) | 2025-10-16 | — | — | WO | disclosed |
| US-20250319214-A1 | A NOVEL KIT FOR RADIOPHARMACEUTICAL PREPARATION OF A RADIOMETAL LABELED CHELATE-FUNCTIONALIZED TARGETING CONJUGATE | Life Molecular Imaging Ltd. (GB) | 2025-10-16 | — | — | US | disclosed |
| US-12427209-B2 | Dual mode 18F-labelled theranostic compounds and uses thereof | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2025-09-30 | — | — | US | disclosed |
| EP-4618991-A1 | PHARMACEUTICAL COMBINATIONS AND USES THEREOF | Novartis AG (CH) | 2025-09-24 | — | — | EP | disclosed |
| US-20240197715-A1 | PHARMACEUTICAL COMBINATIONS AND USES THEREOF | NOVARTIS AG (CH) | 2024-06-20 | — | — | US | disclosed |
| WO-2024105610-A1 | PHARMACEUTICAL COMBINATIONS AND USES THEREOF | NOVARTIS AG (CH) | 2024-05-23 | — | — | WO | disclosed |
| EP-3909948-B1 | BIFUNCTIONAL DO2PA DERIVATIVES, CHELATES WITH METALLIC CATIONS AND USE THEREOF | CENTRE NAT RECH SCIENT (FR) | 2024-02-28 | — | — | EP | disclosed |
| US-20220062446-A1 | DUAL MODE 18F-LABELLED THERANOSTIC COMPOUNDS AND USES THEREOF | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12427209-B2 | Dual mode 18F-labelled theranostic compounds and uses thereof | TFRC, SLC39A3, SLC39A14 | GRPR 529/4885NMBR 261/4885GLP1R 873/4885 |
| US-20240197715-A1 | PHARMACEUTICAL COMBINATIONS AND USES THEREOF | WRN, RECQL, BLM | GRPR 2759/4885NMBR 3601/4885GLP1R 1636/4885 |
| US-20220062446-A1 | DUAL MODE 18F-LABELLED THERANOSTIC COMPOUNDS AND USES THEREOF | TFRC, SLC39A3, SLC39A14 | GRPR 529/4885NMBR 261/4885GLP1R 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.